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LONGITUDINAL ASSESSMENT OF QUALITY OF LIFE AND SYMPTOMS OF
ETHNICALLY DIVERSE BLOOD AND MARROW TRANSPLANTATION PA-
TIENTS
Neumann, J.L.1, Cohen, M.Z.1, Mendoza, T.1, Giralt, S.1,
Cleeland, C.1 1The University of Texas MD Anderson Cancer Center,
Houston, TX.
Several investigators in the nursing, medicine, and psychology
have examined the effects of BMT on quality of life (QOL).
Several studies indicated a signiﬁcant reduction in QOL and per-
sistent symptoms of fatigue, insomnia, anorexia, and nausea in the
ﬁrst year after BMT (Kopp, Schweigkoﬂer, Holzner, et al. 1998,
Winer, Lindley, Hardee, et al. 1999, Hann, Jacobsen, Martin, et al.
1997). The long-term impact of BMT on QOL has been examined
(Andrykowski, Carpenter, et al. 1997, Andrykowski, Brady, et al.
1995 and Andrykowski, Bishop, Hahn, Cella, et al, 2005). None of
these studies examined differences of QOL and symptoms among
ethnically diverse groups of patients.
In our recently completed National Institute of Health sponsored
study, the correlation of quality of life and symptoms were evalu-
ated at multiple time points over the course of 100 days in 164
African-Americans (n24), Hispanic (n38) and non-minority
(n102) patients. The Functional Assessment of Cancer Therapy
(FACT-BMT) measuring quality of life and MD Anderson Symp-
tom Inventory (MDASI) assessing symptoms and symptom inter-
ference with life were used in the study. Other variables examined
included disease, type of transplant, age, graft vs. host disease
(GVHD) and survival. Preliminary results indicate that patients
receiving myeloablative regimen experienced severe symptoms
such as fatigue (p0.02) and pain (p0.03) and poorer QOL
(p0.01) across time. Symptom severity correlates (r -0.59 to
-0.75) with QOL across time. In addition, there were no signiﬁcant
differences in symptom severity, symptom interference and ECOG
performance status between Hispanic and African-Americans over
time. There were signiﬁcant differences in symptom severity,
symptom interference, and ECOG performance across time in
both minority and non-minority groups of BMT patients. Results
of this study add to the knowledge related to symptom clusters and
QOL with this treatment modality and help to guide development
of relevant patient teaching material.
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CHOICE OF DIET AS PART OF TREATMENT FOR GI GVHD
Niangar, G.A.1 1MD Anderson Cancer Center, Houston, TX.
Purpose: To determine which diet can be used to help decrease
amount of diarrhea as associated with GI GVHD (gastrointestinal
graft-versus-host-disease)
Methods: Based on our institution’s guidelines for nutritional
support of patient’s undergoing GI GVHD after allogeneic stem
cell transplant.
Result: There are 4 levels of diet that is used for GI GVHD;
patients are placed on these diets depending on the severity of their
symptoms.
Conclusion: GI GVHD is a major complication after allogeneic
hematopoeitic stem cell transplantation. This can cause diarrhea,
nausea, vomiting, abdominal cramping and pain. With large
amounts of diarrhea, for instance in Stage 4 GI GVHD (severe
cramps with or without ileus), the physician may ask the patient not
to eat or drink for a few days to allow the GI (gastrointestinal) tract
to rest. In MD Anderson a four-stage diet, intended for stem cell
transplant patients who experience symptoms from graft-versus-
host disease is utilized. Dietary recommendation varies from noth-
ing-by-mouth for the most severe (Stage 4) to limiting high fat and
ﬁber foods for 500-1000 ml diarrhea (Stage 1). Calories, proteins,
vitamins and minerals are provided through initiation of total
parenteral nutrition (TPN) to meet their nutritional needs while
on diet restriction.
While nutrition is monitored, multidrug therapies are started as
well, such as steroids, antithymoglobulin and other newer agents
like Inﬂiximab. The patient’s compliance to the diet prescribed is
of utmost importance to help minimize symptoms of GI GVHD.
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REDUCING CENTRAL VENOUS CATHETER RELATED BLOODSTREAM
INFECTIONS IN CHILDREN WITH CANCER
Norville, R.1, Horvath, B.1, Lee, D.1, Hyde, A.1, Gregurich, M.A.1,
Hilburn, J.1, Versalovic, J.2, Mueller, B.2, Stark, J.2, Hockenberry, M.2
1Texas Children’s Hospital, Houston, TX; 2Baylor College of Medicine,
Houston, TX.
The purpose of this study was to determine whether a compre-
hensive educational program inﬂuenced the incidence of hub col-
onization of central venous catheters (CVC) and bloodstream in-
fection (BSI) rates in children with cancer.
CVC infections rates in children with cancer range from 1.0 to
4.58 per 1000 catheter days. CVC hub sites provide bacterial access
to the bloodstream and hub colonization rates in adults vary from
29%-38%. Previous studies show that increasing staff and paren-
teral awareness with education that emphasizes aseptic technique
can decrease catheter infection rates.
A total of 121 registered nurses attended a one-hour educational
program that included a didactic component, a hands-on clinical
simulation and pre- and post-education learning assessments. Prior
to the education program, 51 catheter hub cultures were obtained
from a convenience sample of 27 children with cancer. Cultures
were obtained by swabbing the threaded area of the catheter hub
after removing the injection cap. A semi-quantitative culture for
bacteria and fungus was obtained. Thirty-nine catheter hub cul-
tures were obtained within 3.5 months after the education program
from 20 children. The mean age of the patients was 8.2 years; 78%
were diagnosed with leukemia and 22% with solid tumors. Sur-
veillance of monthly catheter-related bloodstream infections was
tracked for a six-month period for bone marrow transplant (BMT)
and general oncology patients upon completion of the staff edu-
cation program.
Pre- and post-education assessment of nursing staff revealed the
post-test mean score of 86.5% was signiﬁcantly better than the
pre-test mean score of 72% (p0.001). Prior to the education
program, 57% of the hubs were culture positive and after the
educational program the proportion of culture positive hubs was
reduced to 36%. The two-proportion test procedure showed sig-
niﬁcant reduction in culture positive hubs following the interven-
tion (p0.043). Post-intervention, BSI rates reduced from 5.59 to
3.35 per 1000 catheter days for BMT patients and from 4.89 to
3.03 per 1000 catheter days for general oncology patients. A log-
linear model showed a signiﬁcant reduction (p0.001) in infection
rates following the educational program for both patient popula-
tions.
The results of this study indicate that a comprehensive educa-
tional program increases nurses’ knowledge of CVC care and
reduces CVC hub colonization and catheter-related bloodstream
infections in children with cancer.
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STEM CELL TRANSPLANTATION FOR OSTEOPETROSIS: ONE CENTER’S
EXPERIENCE
O’Connor, M.P.1, Myers, K.1, Melone, M.1, Lehmann, L.1 1Dana
Farber Childrens Cancer Care, Boston, MA.
Osteopetrosis is a rare metabolic disorder characterized by ab-
normally dense bones due to a defect in the osteoclasts, the cells
responsible for bone resorption. Osteopetrosis generally presents
in infancy. Infants are brought to medical attention through inci-
dental skeletal radiographs and hypocalcemic seizures. Patients
with osteopetrosis are at high risk for morbidity and mortality.
They may present with pancytopenia, cranial nerve abnormalities
and respiratory difﬁculties. Pancytopenia is caused by the overpro-
duction of bone, which results in obliteration of the marrow cavity.
Loss of vision and hearing is a direct result of narrowing of the
cranial foramina. Respiratory difﬁculties are thought to occur due
to narrowing of the nasal passages and the relatively immobile rib
cage restricting lung movement. Osteoclasts are derived from he-
matopoietic stem cells and thus, by providing donor osteoclasts,
allogeneic stem cell transplant (SCT) can be curative.
From 1997 though 2005, ﬁve patients with osteopetrosis received
allogeneic stem cell transplants at Dana Farber Children’s Cancer
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